Effects of Semaglutide on Alzheimer’s Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.